Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Cash and Equivalents of $3.12 billion for fiscal year 2025.
REGENERON PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $3.12B | +25.3% |
| 2024 | $2.49B | -8.9% |
| 2023 | $2.73B | -12.1% |
| 2022 | $3.11B | +7.6% |
| 2021 | $2.89B | +31.5% |
| 2020 | $2.19B | +35.6% |
| 2019 | $1.62B | +10.2% |
| 2018 | $1.47B | +80.6% |
| 2017 | $812.70M | +51.8% |
| 2016 | $535.20M | -33.9% |
| 2015 | $809.10M | +24.7% |
| 2014 | $648.72M | +21.1% |
| 2013 | $535.61M | +132.6% |
| 2012 | $230.28M | -52.4% |
| 2011 | $483.61M | +329.6% |
| 2010 | $112.57M | -45.6% |
| 2009 | $207.07M | -16.4% |
| 2008 | $247.80M | -50.3% |
| 2007 | $498.93M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.51B | +24.6% | +25.6% |
| June 30, 2025 | $2.00B | +3.9% | -35.4% |
| March 31, 2025 | $3.09B | +18.8% | +24.2% |
| December 31, 2024 | $2.49B | -8.9% | +23.7% |
| September 30, 2024 | $2.01B | -6.5% | +4.7% |
| June 30, 2024 | $1.92B | -0.9% | -26.2% |
| March 31, 2024 | $2.60B | -33.6% | -4.7% |
| December 31, 2023 | $2.73B | -12.1% | +26.8% |
- REGENERON PHARMACEUTICALS, INC. showed an increase of +25.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, REGENERON PHARMACEUTICALS, INC.’s cash and equivalents has grown by 525.0% (from $498.93 million to $3.12 billion).
- The most recent figure is from REGENERON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: